Verona Pharma (VRP)

 

VRP Share PerformanceMore

52 week high210.00 24/10/16
52 week low120.75 17/02/17
52 week change -28.25 (-17.52%)
4 week volume309,999 04/04/17

Media for (VRP)

Presenter: Jan-Anders Karlsson
28/07/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Director Deals - Verona Pharma PLC (VRP)

Dr David Ebsworth, Chairman, 13,373 shares in the company on the 27th April 2017 at a price of 132.00p. The Director now...

Director/PDMR Shareholding

RNS Number: 7827D Verona Pharma PLC 28 April 2017 Verona Pharma Announces Director Purchases and Related Party Transactions April 28, 2017, LONDON - Verona Pharma plc (AIM: VRP) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory dis...

Pricing of Offering and Approval to List on NASDAQ

RNS Number: 4835D Verona Pharma PLC 27 April 2017 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOU...

Global Offering and Application to List on NASDAQ

RNS Number: 6578C Verona Pharma PLC 19 April 2017 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Verona Pharma Announces Launch of Global Offering and Application to List on the NASDAQ Global Market 19 April 2017, London - Verona Pharma plc (AIM: V...

FDA authorises start of Verona Pharma's US trial

Verona Pharma announced the US Food and Drug Administration (FDA) authorized the initiation of a pharmacokinetic ...

FDA Authorisation to Proceed RPL554 Investigation

RNS Number: 5435C Verona Pharma PLC 18 April 2017 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014. Verona Pharma Receives Authorization from the U.S. FDA to Proceed with Clinical Investigation of RPL554 with the Acceptance of Investigational New Drug Applic...

All resolutions passed at Verona AGM

Verona Pharma has confirmed that all resolutions proposed at the Annual General Meeting (AGM) held today were duly ...

Result of AGM

RNS Number: 3537C Verona Pharma PLC 12 April 2017 Verona Pharma plc ("Verona Pharma" or the "Company") Result of AGM 12 April 2017, London -Verona Pharma plc (AIM: VRP.L), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases, announces that all reso...

Fundamental DataMore

EPS-0.74
Dividend yield0 %

Equity Research (VRP)

edison investment research
Verona Pharma plc
26/07/2016
Verona’s £44.7m gross raise removes funding uncertainty, allowing the company to focus on the clinical progress of its respiratory asset RPL554, a dual PDE3/PDE4 inhibitor. RPL554 is in development...
hardman & co
Verona Pharma plc
20/06/2016
VRP is developing first-in-class drugs to treat unmet medical needs in respiratory disease. Over the last two years’ VRP has reported positive outcomes from a five stage Phase I/IIa programme which...
hardman & co
Verona Pharma plc
16/03/2016
VRP is developing first-in-class drugs that treat unmet medical needs in respiratory disease. RPL554 is being fast-tracked to commercialisation by focusing on a $3.2bn market segment poorly serviced...

Latest discussion posts More

  • Re: Website

    from which you will note latest filings 280417 lots in there - should you so wish to read over this long weekend or perhaps not - lol bw all mol
    29-Apr-2017
    mol42
  • RNS 280417

    so we now know how much our Chairman's further investment was Dr David Ebsworth- 13,373 #17,652.36 total holding now 117,657 shares leaving 240,726 shares at 1.32 by an ...
    29-Apr-2017
    mol42
  • Website

    now updated to show SEC Filings in addition to RNS http://investors.veronapharma.com/sec-filings mol
    27-Apr-2017
    mol42

Users' HoldingsMore

Users who hold Verona Pharma also hold..
LLOYDS GRP.19%
GULF KEYSTONE11%
RANGE RES.11%
BP10%
RENEURON10%

Codes & Symbols

ISINGB00BYW2KH80
SymbolsVRP, LSE:VRP, VRP.L, VRP:LN, LON:VRP, XLON:VRP